PET-CT in Clinical Adult Oncology-IV. Gynecologic and Genitourinary Malignancies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jun 24

PMID 35740665

Authors

Ahmed Ebada Salem

Gabriel C Fine

Matthew F Covington

Bhasker R Koppula

Richard H Wiggins

John M Hoffman

Kathryn A Morton

Affiliations

Soon will be listed here.

Abstract

Concurrently acquired positron emission tomography and computed tomography (PET-CT) is an advanced imaging modality with diverse oncologic applications, including staging, therapeutic assessment, restaging and longitudinal surveillance. This series of six review articles focuses on providing practical information to providers and imaging professionals regarding the best use and interpretative strategies of PET-CT for oncologic indications in adult patients. In this fourth article of the series, the more common gynecological and adult genitourinary malignancies encountered in clinical practice are addressed, with an emphasis on Food and Drug Administration (FDA)-approved and clinically available radiopharmaceuticals. The advent of new FDA-approved radiopharmaceuticals for prostate cancer imaging has revolutionized PET-CT imaging in this important disease, and these are addressed in this report. However, [F]F-fluoro-2-deoxy-d-glucose (FDG) remains the mainstay for PET-CT imaging of gynecologic and many other genitourinary malignancies. This information will serve as a guide for the appropriate role of PET-CT in the clinical management of gynecologic and genitourinary cancer patients for health care professionals caring for adult cancer patients. It also addresses the nuances and provides guidance in the accurate interpretation of FDG PET-CT in gynecological and genitourinary malignancies for imaging providers, including radiologists, nuclear medicine physicians and their trainees.

Citing Articles

Investigation of the distribution of inguinal lymph nodes and delineation of the inguinal clinical target volume using F-FDG PET/CT.

Han J, Qi Y, Liu J, Yan X, Zhang W, Yuan L BMC Cancer. 2024; 24(1):1254.

PMID: 39390445 PMC: 11465914. DOI: 10.1186/s12885-024-13015-w.

Incidental endometrial cancer detected on FDG PET/CT imaging for melanoma.

Shagun , Kim A, Koshevarova V, Mohammadinejad P, Murphy M, Bhargava P Radiol Case Rep. 2024; 19(7):2845-2848.

PMID: 38689809 PMC: 11059307. DOI: 10.1016/j.radcr.2024.03.058.

Clinical practice in prostate PET imaging.

Huls S, Burkett B, Ehman E, Lowe V, Subramaniam R, Kendi A Ther Adv Med Oncol. 2023; 15:17588359231213618.

PMID: 38028142 PMC: 10666681. DOI: 10.1177/17588359231213618.

18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.

Jena R, Bhargava P, Tripathi S, Taywade S, Yadav T, Sandhu A BJUI Compass. 2023; 4(6):662-667.

PMID: 37818027 PMC: 10560619. DOI: 10.1002/bco2.246.

Long Axial Field-of-View PET/CT Could Answer Unmet Needs in Gynecological Cancers.

Triumbari E, Rufini V, Mingels C, Rominger A, Alavi A, Fanfani F Cancers (Basel). 2023; 15(9).

PMID: 37173874 PMC: 10177015. DOI: 10.3390/cancers15092407.

References

Hoberuck S, Lock S, Winzer R, Zophel K, Froehner M, Fedders D . [Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. EJNMMI Res. 2020; 10(1):135. PMC: 7647983. DOI: 10.1186/s13550-020-00723-0. View

Fendler W, Calais J, Eiber M, Flavell R, Mishoe A, Feng F . Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019; 5(6):856-863. PMC: 6567829. DOI: 10.1001/jamaoncol.2019.0096. View

Rogers L . Management of Advanced Squamous Cell Carcinoma of the Vulva. Cancers (Basel). 2022; 14(1). PMC: 8750777. DOI: 10.3390/cancers14010167. View

Oldan J, Sullivan S . Positron emission tomography-computed tomography for inguinal nodes in vulvar cancer. World J Nucl Med. 2018; 17(3):139-144. PMC: 6034544. DOI: 10.4103/wjnm.WJNM_32_17. View

Gorospe L, Jover-Diaz R, Vicente-Bartulos A . Spectrum of PET-CT pelvic pitfalls in patients with gynecologic malignancies. Abdom Imaging. 2012; 37(6):1041-65. DOI: 10.1007/s00261-012-9867-5. View

Maruyama S, Sato Y, Satake Y, Mise H, Kim T . Diffusion-Weighted MRI and FDG-PET in Diagnosis of Endometrial Stromal Nodule. Case Rep Obstet Gynecol. 2015; 2015:540283. PMC: 4324744. DOI: 10.1155/2015/540283. View

Kilcoyne A, Gottumukkala R, Kang S, Akin E, Hauck C, Hindman N . ACR Appropriateness Criteria® Staging and Follow-up of Primary Vaginal Cancer. J Am Coll Radiol. 2021; 18(11S):S442-S455. DOI: 10.1016/j.jacr.2021.08.011. View

Crivellaro C, Guglielmo P, De Ponti E, Elisei F, Guerra L, Magni S . 18F-FDG PET/CT in preoperative staging of vulvar cancer patients: is it really effective?. Medicine (Baltimore). 2017; 96(38):e7943. PMC: 5617695. DOI: 10.1097/MD.0000000000007943. View

Hofman M, Lawrentschuk N, Francis R, Tang C, Vela I, Thomas P . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020; 395(10231):1208-1216. DOI: 10.1016/S0140-6736(20)30314-7. View

10.

Roussel E, Capitanio U, Kutikov A, Oosterwijk E, Pedrosa I, Rowe S . Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. Eur Urol. 2022; 81(5):476-488. PMC: 9844544. DOI: 10.1016/j.eururo.2022.01.040. View

11.

Girard A, Vila Reyes H, Shaish H, Grellier J, Dercle L, Salaun P . The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma. Front Oncol. 2020; 10:565086. PMC: 7574640. DOI: 10.3389/fonc.2020.565086. View

12.

Han L, Wang Q, Zhao L, Feng X, Wang Y, Zou Y . A Systematic Review and Meta-Analysis of the Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Locally Advanced Cervical Cancer Treated with Concomitant Chemoradiotherapy. Diagnostics (Basel). 2021; 11(7). PMC: 8304455. DOI: 10.3390/diagnostics11071258. View

13.

Mapelli P, Mangili G, Picchio M, Gentile C, Rabaiotti E, Giorgione V . Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia. Eur J Nucl Med Mol Imaging. 2013; 40(4):505-13. DOI: 10.1007/s00259-012-2324-4. View

14.

Akin-Akintayo O, Jani A, Odewole O, Tade F, Nieh P, Master V . Change in Salvage Radiotherapy Management Based on Guidance With FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer. Clin Nucl Med. 2016; 42(1):e22-e28. PMC: 5138124. DOI: 10.1097/RLU.0000000000001379. View

15.

Schuster D, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y . Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014; 55(12):1986-92. PMC: 4844004. DOI: 10.2967/jnumed.114.143628. View

16.

Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann C, Meller B . Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?. Int Braz J Urol. 2019; 45(3):459-467. PMC: 6786102. DOI: 10.1590/S1677-5538.IBJU.2018.0305. View

17.

Kitajima K, Murakami K, Kaji Y, Sugimura K . Spectrum of FDG PET/CT findings of uterine tumors. AJR Am J Roentgenol. 2010; 195(3):737-43. DOI: 10.2214/AJR.09.4074. View

18.

Zhao Y, Wu C, Li W, Chen X, Li Z, Liao X . 2-[F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2020; 48(2):570-579. DOI: 10.1007/s00259-020-04996-4. View

19.

Sadeghi R, Zakavi S, Hasanzadeh M, Treglia G, Giovanella L, Kadkhodayan S . Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature. Int J Gynecol Cancer. 2013; 23(8):1349-56. DOI: 10.1097/IGC.0b013e3182a20e18. View

20.

Jadvar H . The VISION Forward: Recognition and Implication of PSMA-/F-FDG+ mCRPC. J Nucl Med. 2021; 63(6):812-815. PMC: 9157736. DOI: 10.2967/jnumed.121.263274. View